Ferric Carboxymaltose API Manufacturers in India

Molecular Formula – C24H44FeO25
Molecular Weight – 788.4mg/mol
Melting Point –
CAS No. – 9007-72-1
Shelf Life – 36 months
Storage Advice – Store at cool, dry room temperature. Do not store over 30 degrees Celsius, and do not freeze. Keep the compound at a distance from other non-compatible compounds. Store in an inert atmosphere away from sunlight.
Packing Size –
HSN Code –

Features – Brown, amorphous Powder
Color – Brown
Solubility –
pH Range – 5.0 – 7.0
LOD (at 105° for 4 Hr) –
Heavy Metals (as Lead) –
Assay (as calcium) –

Drug Uses

FERRIC CARBOXYMALTOSE is a great source of iron, and the compound is used to treat people with anemia. It is a state of iron deficiency in the body that reduces the hemoglobin count. The compound belongs to the anti-anemic medicines group. It is usually taken as a supplement for iron deficiency in the body which cannot be fulfilled by food consumption. As one of the Best Chemical Industries In India, WBCIL offers the best quality of this compound for medical and pharmaceutical uses. WBCIL is one of the leading Industrial Chemical Suppliers In India that offers pharmaceutical and chemical compounds that precisely meet all the bars of industrial criteria.

Food uses

The compound is not widely used in the food industry as it is specially developed and used for the pharmaceutical industry only.

Single Dose of Intravenous Ferric Carboxymaltose Prevents Anemia for 6 Months among Moderately or Severely Anemic Postpartum Women: A Case Study from India

ABSTRACT The effectiveness of intravenous ferric carboxymaltose (FCM) in quickly increasing normal hemoglobin concentration and replenishing body iron reserves up to 6–12 wk is known; however, its long-term effectiveness is unknown. In this study conducted in northern India during August...

Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: A randomized controlled trial

Abstract Background Perioperative anemia is common in cardiac surgery. Few studies investigated the effect of postoperative intravenous (IV) iron supplementation and were mostly inconclusive. Methods Design: A randomized single-center, double-blind, placebo-controlled, parallel-group trial. Participants: 195 non-anemic patients were recruited from...

Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial

Author links open overlay panel Nanja Bevers MD 1, Els Van de Vijver PhD, MD 2, Arta Aliu 1, Ashkan Rezazadeh Ardabili MD 3, Philippe Rosias MD, PhD 1, Janneke Stapelbroek MD, PhD 4, Imke A. Bertrams Maartens MD 5,...

Abstract 13788: Intravenous Iron Replacement Therapy With Ferric Carboxymaltose is Safe and Effective in Pediatric Patients With Heart Failure

Abstract Introduction: Iron deficiency (ID) is associated with worse outcomes in patients with heart failure (HF). In adults with HF and ID, intravenous (IV) iron replacement therapy (IRT) improves HF outcomes and is the first-line therapy for ID because oral...

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency

Background: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak oxygen consumption [peak VO2], an objective measure...

Abstract 12081: Beneficial Effects of Ferric Carboxymaltose in Patients With Pulmonary Arterial Hypertension and Iron Deficiency: A Long-term Study

Introduction: PAH is a progressive disease with limited prognosis. Iron deficiency (ID) correlates in PAH patients with disease severity and mortality. Oral iron resorption is impaired by hepcidine in PAH. In a former pilot study, we could demonstrate a short-term...